Results 51 to 60 of about 4,771 (191)

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 9, Page 2986-3001, September 2026.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan   +24 more
wiley   +1 more source

Epigenetic Therapy with Belinostat Stabilizes Unresectable HCC [PDF]

open access: yesCancer Discovery, 2012
Abstract A phase I/II study in HCC shows that the HDAC inhibitor belinostat safely leads to disease stabilization.
openaire   +1 more source

Identification of belinostat metabolites in human plasma using HPLC-DAD & LC-MS/MS analyses.

open access: yes, 2013
Identification of belinostat metabolites in human plasma using HPLC-DAD & LC-MS/MS analyses.
Win-Lwin Thuya (277890)   +16 more
core   +1 more source

Discovery of Spirochromanone‐Based Molecular Hybrids as Promising Anticancer Leads: An Integrated Experimental and Theoretical Study

open access: yesChemistrySelect, Volume 11, Issue 31, 17 August 2026.
This work shows the new class of spirochromanone‐based molecular hybrids as promising anticancer agents. Several compounds displayed promising activity against RAMOS cells with an IC50 range of 1.11–1.47 µM, and CCRF‐CEM cells with an IC50 range of 7.71–13.55 µM.
Ramesh Reddy Mudda   +8 more
wiley   +1 more source

Recent Prospectives of Anticancer Histone Deacetylase Inhibitors [PDF]

open access: yesJournal of Advanced Biomedical and Pharmaceutical Sciences, 2019
Histone deacetylases (HDACs) are common targets for cancer therapy as they are expressed in many forms of cancers; several research studies have been introduced discussing the design of small molecules that target this abnormal epigenetic changes ...
Shymaa Abbass   +4 more
doaj   +1 more source

Supplementary Data from Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma

open access: yes, 2010
Supplementary Data from Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell ...
Enrica Marchi (14976762)   +5 more
core   +1 more source

HAUS5 defines a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent epithelial–mesenchymal plasticity program and therapeutic vulnerability to Belinostat in clear cell renal cell carcinoma

open access: yesTranslational Oncology
Clear cell renal cell carcinoma (ccRCC) is characterized by high aggressiveness and limited therapeutic options. However, the molecular determinants driving ccRCC progression and therapeutic vulnerability remain incompletely defined.
Youwei Chi   +11 more
doaj   +1 more source

DRAM1‐defined autophagy‐JAK‐STAT‐Tregs axis drives immunosuppression and predicts immunotherapy response in pan‐cancer

open access: yesClinical and Translational Discovery, Volume 6, Issue 3, June 2026.
Tumour‐intrinsic DRAM1, induced by DNA damage and IFN‐γ, activates an autophagy/JAK‐STAT axis that recruits Tregs, causing CD8+ T cell exhaustion and establishing a self‐sustaining, immunotherapy‐resistant “cold” tumour microenvironment. Abstract Background DNA damage‐regulated autophagy modulator 1 (DRAM1) is a lysosomal protein involved in autophagy ...
Jinchun Wu   +7 more
wiley   +1 more source

Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells

open access: yesMolecular Cancer, 2008
Background Histone acetylation is an epigenetic modification involved in the regulation of gene expression, balanced by histone acetyl transferases and histone deacetylase (HDAC) enzymes.
Dejligbjerg Marielle   +8 more
doaj   +1 more source

Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation

open access: yesMedComm – Oncology, Volume 5, Issue 2, June 2026.
The abnormal overexpression or gain‐of‐function mutations of EZH2 play a significant role in cancer occurrence and progression, highlighting the importance and potential of EZH2 as a cancer biomarker. Therefore, screening for effective and safe small‐molecule inhibitors, degraders, and natural compounds targeting EZH2 through preclinical cancer models ...
Xi Zhong   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy